These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

240 related items for PubMed ID: 15127079

  • 1. Improvements in neurocognitive function and mood following adjunctive treatment with mifepristone (RU-486) in bipolar disorder.
    Young AH, Gallagher P, Watson S, Del-Estal D, Owen BM, Ferrier IN.
    Neuropsychopharmacology; 2004 Aug; 29(8):1538-45. PubMed ID: 15127079
    [Abstract] [Full Text] [Related]

  • 2. Effects of adjunctive mifepristone (RU-486) administration on neurocognitive function and symptoms in schizophrenia.
    Gallagher P, Watson S, Smith MS, Ferrier IN, Young AH.
    Biol Psychiatry; 2005 Jan 15; 57(2):155-61. PubMed ID: 15652874
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Persistent effects of mifepristone (RU-486) on cortisol levels in bipolar disorder and schizophrenia.
    Gallagher P, Watson S, Elizabeth Dye C, Young AH, Nicol Ferrier I.
    J Psychiatr Res; 2008 Oct 15; 42(12):1037-41. PubMed ID: 18255098
    [Abstract] [Full Text] [Related]

  • 5. A randomized trial to examine the effect of mifepristone on neuropsychological performance and mood in patients with bipolar depression.
    Watson S, Gallagher P, Porter RJ, Smith MS, Herron LJ, Bulmer S, North-East Mood Disorders Clinical Research Group, Young AH, Ferrier IN.
    Biol Psychiatry; 2012 Dec 01; 72(11):943-9. PubMed ID: 22770649
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Clinical and biological effects of mifepristone treatment for psychotic depression.
    Flores BH, Kenna H, Keller J, Solvason HB, Schatzberg AF.
    Neuropsychopharmacology; 2006 Mar 01; 31(3):628-36. PubMed ID: 16160710
    [Abstract] [Full Text] [Related]

  • 8. A randomized, double-blind, controlled trial evaluating the effect of intranasal insulin on neurocognitive function in euthymic patients with bipolar disorder.
    McIntyre RS, Soczynska JK, Woldeyohannes HO, Miranda A, Vaccarino A, Macqueen G, Lewis GF, Kennedy SH.
    Bipolar Disord; 2012 Nov 01; 14(7):697-706. PubMed ID: 23107220
    [Abstract] [Full Text] [Related]

  • 9. Randomized placebo-controlled adjunctive study of an extract of withania somnifera for cognitive dysfunction in bipolar disorder.
    Chengappa KN, Bowie CR, Schlicht PJ, Fleet D, Brar JS, Jindal R.
    J Clin Psychiatry; 2013 Nov 01; 74(11):1076-83. PubMed ID: 24330893
    [Abstract] [Full Text] [Related]

  • 10. Rapid reversal of psychotic depression using mifepristone.
    Belanoff JK, Flores BH, Kalezhan M, Sund B, Schatzberg AF.
    J Clin Psychopharmacol; 2001 Oct 01; 21(5):516-21. PubMed ID: 11593077
    [Abstract] [Full Text] [Related]

  • 11. Recombinant human erythropoietin to target cognitive dysfunction in bipolar disorder: a double-blind, randomized, placebo-controlled phase 2 trial.
    Miskowiak KW, Ehrenreich H, Christensen EM, Kessing LV, Vinberg M.
    J Clin Psychiatry; 2014 Dec 01; 75(12):1347-55. PubMed ID: 25099079
    [Abstract] [Full Text] [Related]

  • 12. Cognitive effects of intravenous hydrocortisone in subjects with PTSD and healthy control subjects.
    Grossman R, Yehuda R, Golier J, McEwen B, Harvey P, Maria NS.
    Ann N Y Acad Sci; 2006 Jul 01; 1071():410-21. PubMed ID: 16891588
    [Abstract] [Full Text] [Related]

  • 13. A randomized, placebo-controlled trial of citicoline add-on therapy in outpatients with bipolar disorder and cocaine dependence.
    Brown ES, Gorman AR, Hynan LS.
    J Clin Psychopharmacol; 2007 Oct 01; 27(5):498-502. PubMed ID: 17873684
    [Abstract] [Full Text] [Related]

  • 14. Cognitive effects of mifepristone in overweight, euthymic adults with depressive disorders.
    Roat-Shumway S, Wroolie TE, Watson K, Schatzberg AF, Rasgon NL.
    J Affect Disord; 2018 Oct 15; 239():242-246. PubMed ID: 30025313
    [Abstract] [Full Text] [Related]

  • 15. Opposite relationships between cannabis use and neurocognitive functioning in bipolar disorder and schizophrenia.
    Ringen PA, Vaskinn A, Sundet K, Engh JA, Jónsdóttir H, Simonsen C, Friis S, Opjordsmoen S, Melle I, Andreassen OA.
    Psychol Med; 2010 Aug 15; 40(8):1337-47. PubMed ID: 19891810
    [Abstract] [Full Text] [Related]

  • 16. Levetiracetam in the management of bipolar depression: a randomized, double-blind, placebo-controlled trial.
    Saricicek A, Maloney K, Muralidharan A, Ruf B, Blumberg HP, Sanacora G, Lorberg B, Pittman B, Bhagwagar Z.
    J Clin Psychiatry; 2011 Jun 15; 72(6):744-50. PubMed ID: 21034692
    [Abstract] [Full Text] [Related]

  • 17. Mifepristone Plasma Level and Glucocorticoid Receptor Antagonism Associated With Response in Patients With Psychotic Depression.
    Block T, Petrides G, Kushner H, Kalin N, Belanoff J, Schatzberg A.
    J Clin Psychopharmacol; 2017 Oct 15; 37(5):505-511. PubMed ID: 28708736
    [Abstract] [Full Text] [Related]

  • 18. Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study).
    Thase ME, Macfadden W, Weisler RH, Chang W, Paulsson B, Khan A, Calabrese JR, BOLDER II Study Group.
    J Clin Psychopharmacol; 2006 Dec 15; 26(6):600-9. PubMed ID: 17110817
    [Abstract] [Full Text] [Related]

  • 19. Possible use of glucocorticoid receptor antagonists in the treatment of major depression: preliminary results using RU 486.
    Murphy BE, Filipini D, Ghadirian AM.
    J Psychiatry Neurosci; 1993 Nov 15; 18(5):209-13. PubMed ID: 8297920
    [Abstract] [Full Text] [Related]

  • 20. Mifepristone versus placebo in the treatment of psychosis in patients with psychotic major depression.
    DeBattista C, Belanoff J, Glass S, Khan A, Horne RL, Blasey C, Carpenter LL, Alva G.
    Biol Psychiatry; 2006 Dec 15; 60(12):1343-9. PubMed ID: 16889757
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.